drugset / Trial / NCT07142798
to Assess the Eradication Rate of 14-day Bismuth/Amoxicillin/PCAB Triple Therapy for the Treatment of Helicobacter Pylori Infection
Enrolling by invitation
200 enrolled
Kaohsiung Medical University
An-Nan Hospital, China Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
To assess the efficacy and safety of 14-day bismuth/amoxicillin/PCAB triple therapy for the treatment of Helicobacter pylori infection in Taiwan
Timeline
- Start
- 2024-09-26
- Primary completion
- 2025-12-31
- Completion
- 2026-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amoxicillin | Other / unclassified | 750 mg | — |
| Subject | Vonoprazan | Other / unclassified | 20 mg | — |
| Subject | tripotassium dicitrate bismuthate | Unknown | 300 mg | — |